About Absolute Biotech
Founded in 2022, Absolute Biotech brings together a portfolio of antibody-focused businesses to provide reagents, kits and specialist services for research, diagnostic and therapeutic applications. The company’s expertise spans antibody annotation, validation, sequencing, engineering and recombinant manufacturing, enabling researchers to work with well-characterized reagents that support reproducibility and downstream development. Through capabilities in recombinant antibody technology, immunohistochemistry validation, flow cytometry reagent development and custom antibody engineering, Absolute Biotech supports applications across immunology, oncology, infectious disease research, drug discovery and translational science.
Its portfolio includes recombinant antibodies, proteins, ELISA and assay kits, flow cytometry reagents, cell lines and custom antibody services delivered through specialist brands including Absolute Antibody, LSBio, Kerafast, Nordic-MUbio, Everest Biotech and Exalpha Biologicals. These products and services support workflows such as target validation, biomarker discovery, antibody characterization, immunohistochemistry, cell analysis and therapeutic antibody development. In addition, the company provides sequencing, validation and recombinant expression services that help convert existing antibodies into sequence-defined recombinant reagents for research and preclinical applications.
Europa Biosite subsidiaries distribute Absolute Biotech products to researchers across Austria, Belgium, Denmark, Estonia, Finland, Iceland, Ireland, Latvia, Lithuania, Luxembourg, Netherlands, Norway, Sweden, Switzerland and the UK.